Half Year Report
RNS & Investor News
02 March 2021
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 2 February 2021 regarding the intention to appoint Stephen Hammond MP as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Stephen will join the Board as a Non-Executive Director with immediate effect. The text below sets out the required disclosures.
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Stephen William Hammond (aged 59):
Appointments in the last five years
Harwood Film Partnership LLP
Commonwealth Parliamentary Association (United Kingdom Branch)
Peal Gas LLC
South Coast Regeneration & Investment Property Co Limited
In December 2020 The Office of the Advisory Committee on Business Appointments noted that whilst Stephen Hammond had complied with the House of Commons regulatory disclosure requirements, he did not seek advice as he was required to do in relation to his role at Public Policy Projects, a think tank policy institute, and as a consequence had breached Government's Rules and the requirement set out in the Ministerial Code.
Stephen Hammond MP does not currently own any shares or options in the Company.
There is no further information regarding Stephen Hammond MP required to be disclosed under the AIM Rules.
Neil Davidson, Chairman of OptiBiotix commented: "We are pleased to confirm the appointment of Stephen Hammond which reflects the continued development of the Company and the ambition of the Board to build a profitable international business with global brands.
"The Company anticipate that there will be further additions and changes to the Board and management teams as it continues to grow sales, expand into international markets and commercialises its next generation products."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the content of this announcement.
For further information, please contact:
OptiBiotix Health plc
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR Ltd
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020